TELA Bio to Present at the Jefferies Virtual Healthcare Conference
Get Alerts TELA Hot Sheet
Join SI Premium – FREE
MALVERN, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference.
TELA Bio's management is scheduled to present on Tuesday, June 2, 2020 at 9:00 AM Eastern Daylight Time (EDT). Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company's website at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA's portfolio is supported by quality, data-driven science and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.
TELA Bio Contact
Stuart Henderson
Vice President, Corporate Development and Investor Relations
TELA Bio, Inc.
484-320-2930
Investor Contact
Greg Chodaczek
347-620-7010
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bilibili Inc. Provides Update on Share Repurchase Program
- LodeStar report shows nominal year-over-year decline in national average mortgage closing costs
- R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share